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INTRODUCTION
Perianal fistulizing Crohn’s disease (PFCD) is 
one of the most aggressive and disabling phenotypes 
of  this important subtype of  inflammatory bowel 
diseases (IBD)(10). Complex and simple fistulas can 
affect the perianal area in 25% to 80% of  Crohn’s 
disease (CD) patients, and are related to significant 
symptoms such as purulent discharge, local oedema, 
soiling and anal discomfort(24). Young patients can be 
often affected by PFCD, with consequent decreased 
quality of life, mainly related to limitations in daily 
and sexual activities.
Complementary tests such as endorectal ultra-
sound, pelvic magnetic ressonance imaging (MRI) 
and examination under anesthesia (EUA) lead to 
nearly 100% of  accuracy in the diagnosis of  the 
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fistula tracks, mainly when used as concomitant 
diagnostic tools(3).
Medical therapy in isolation for PFCD is associa-
ted with significant limitations, mainly in conven-
tional treatment. Antibiotics such as metronidazole 
and ciprofloxacin can be used with variable success 
rates, but recurrence is quite frequent after treatment 
discontinuation, that can occur due to important 
adverse events(4, 21). Immunomodulators (azathioprine 
or 6-mercaptopurine) also can lead to reduction of 
purulent discharge, and are often used in clinical 
practice(15). However, clinical data from prospective 
trials are scarce and limited with these agents(14).
The use of  tumor-necrosis-factor antagonists 
(anti-TNF agents), like Infliximab (IFX)(16, 19) and 
Adalimumab (ADA)(5), can lead to an improve of the 
inflammation of perianal fistulas related to CD. One 
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study even demonstrated that the association of ADA with 
ciprofloxacin had lead to better results than the use of ADA as 
monotherapy(6). These drugs were studied in some prospective 
trials, and up to date, anti-TNF agents seem to be the most 
powerful medications in the management of this phenotype 
of  CD(5, 6, 16, 19), when properly indicated. However, some 
retrospective populational studies had demonstrated that in 
the biological era, there was an increase in the occurrence of 
perianal abscesses with biological agents alone, possibly due 
to the closure of the external openings at the skin level, with 
persistence of the inflammatory process at the fistula tracks(11).
Surgical procedures, in isolation or combined with con-
ventional therapy (immunomodulators or antibiotics), can 
also improve the inflammation on the perineum of  these 
patients, although there are clear limitations in the results of 
the studies previously published(18). Fistulotomies are often an 
adequate way of treating superficial intersphincteric fistulas. 
Advancement flaps can also heal the fistulas in CD patients, 
mainly in the absence of active proctitis(12).
Combined therapy with anti-TNF agents and seton 
placement during EUA seems to be the most effective form 
of treatment of PFCD(2, 7, 8). The curettage of the fistula tracks 
associated with the economic excision of  the inflammed 
external openings prepare the perianal tissue for the proper 
action of biological agents. Regueiro et al. have studied the 
efficacy of IFX in PFCD, and demonstrated that the hea-
ling rates were higher and recurrence rates were lower when 
the biological agent was associated with seton placement, 
as compared to its use in isolation(17). Gaertner et al. also 
demonstrated similar results, showing 42% of healing rates 
in patients treated with seton placement associated with 
IFX, a higher index as compared to surgery alone (18%)(8).
There are several outcomes to be achieved as a result 
of  the approach to PFCD described in the literature, as a 
reduction of  50% of  fistula drainage, closure of  external 
fistulas and complete healing(8, 16, 19). Some patients remain 
well even maintaining their setons during biological therapy. 
Few case series had studied the outcome of complete perianal 
remission, with abscence of drainage and withdrawal of the 
setons, with a completely healed perineum.
The aim of this study was to check the rates of perianal 
complete remission in a case series of  PFCD Brazilian 
patients, previously submitted to combined therapy (seton 
placement during EUA followed by anti-TNF induction and 
maintenance therapy). Secondary objectives were to analyze 
the presence of recurrence of active PFCD after remission, 
and the timing for its occurrence.
METHODS
Study design
This was a retrospective observational study, with con-
secutive patients from four referral IBD units in Brazil, 
submitted to combined therapy for PFCD, treated between 
January 2005 and November 2011, followed until July 2012. 
The analysis was performed with a complete electronic chart 
review after identification of the patients from operating lists 
from the referral units. Data was fulfilled by four different 
physicians, according to an established protocol. The anal-
ysis did not use any control group to compare the variables.
Inclusion and exclusion criteria
In this study, we included patients with CD at any age, 
diagnosed by clinical symptoms and imaging tests, associated 
with endoscopic examinations with biopsies. Patients with 
PFCD (with simple or complex fistulas), that were treated 
with EUA, seton placement and subsequent anti-TNF ther-
apy (IFX or ADA) initiation, with induction followed by 
maintenance regimen, were included in this analysis.
Patients with missing data in the charts, with non-fist-
ulizing perianal CD (skin tags, fissures and hemorrhoids, 
for example), submitted to other perianal procedures (fis-
tulotomies for superficial fistulas or advancement flaps) or 
patients that were treated with medical therapy in isolation 
(with antibiotics or immunomodulators) were excluded from 
this analysis. Patients with recto-vaginal fistulas and with an-
ti-TNF therapy administered before the surgical procedures 
were also excluded.
Demographics and clinical variables
The clinical variables analyzed were: demographic data (age 
at the beggining of the treatment, genre), Montreal classifica-
tion, concomitant medication at combined therapy initiation 
(steroids or immunomodulators), type of perianal fistula (sim-
ple or complex), time of follow-up, number of EUA performed 
during combined therapy, seton withdrawal (if  performed, 
the timing of its occurrence), presence of complete perianal 
remission, presence and timing of recurrence. The fistulae 
were classified as simple or complex based on the American 
Gastroenterological Association classification, published in 
2003(1). Fistulae were considered simple when a lower track 
was found (intersphincteric, for example), with a single external 
opening, no complications as abscesses and strictures, without 
active proctitis. On the other hand, they were considered com-
plex when a higher track was identified (suprasphincteric, for 
example), with multiple external openings, possibly associated 
with stenosis, abscesses and active proctitis.
Patients protocol
All patients from the four referral IBD units were treated 
with combined therapy. They were submitted to EUA (with 
general or spinal anesthesia), the fistula tracks were explored 
and a simple curettage was performed, associated with exci-
sion of external openings when needed. Rubber-made setons 
were passed through the tracks with fixation by the overlap-
ping technique, performed with simple knots of doubled 0 
cotton strings (Figure 1).
After EUA and seton placement, the type of agent (IFX 
or ADA) was chosen in accordance to a patient and physician 
consensus, and anti-TNF therapy was initiated. IFX was 
initiated with the regular induction regimen of intravenous 
5 mg/kg in weeks 0, 2 and 6, followed by maintenance infu-
sions with the same dose every 8 weeks. ADA induction was 
performed with subcutaneous injections of 160 mg at week 
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0, 80 mg at week 2 and 40 mg every other week after week 4. 
The initiation of biological therapy with both agents could 
occur right after the EUA (in the same admission) until 14 
days after seton placement. All patients included did not use 
previously any anti-TNF agent (they were naïve to biolog-
ical therapy). During anti-TNF therapy, the patients could 
be treated with concomitant immunomodulators such as 
azathio prine or 6-mercaptopurine, or with biological mono-
therapy. All patients used antibiotics for at least 2 weeks after 
the EUA and anti-TNF initiation.
Patients were then followed in outpatient setting, and 
could have their setons removed according to individual 
case-based decisions, mainly after rigid proctoscopies that 
demonstrated abscence of rectal inflammation. This seton 
removal could be performed any time during the follow-up 
visits. Patients were allowed to maintain their setons, if  that 
was their option. Additional EUA and curettage of the fis-
tula tracks could be performed according to the surgeon’s 
perception of indication.
Outcome measurement and defi nitions
The primary objective of this study was to evaluate the 
rates of complete perianal remission, which was defined as 
complete absence of  perianal drainage from fistula tracks 
with gentle finger pressure, associated with seton with drawal 
(complete closure of  all fistula tracks, without setons). 
Patients that had absence of drainage that wanted to keep 
their setons in place were allowed to maintain them, but were 
considered as having not achieved this outcome. These were 
considered to have remission with setons (partial response). 
The others that had still persistance of drainage with setons, 
were considered to have active PFCD.
Secondary objectives were to analyze recurrence rates 
in the patients that achieved complete perianal remission, 
and the timing for its occurrence. Recurrence was defined as 
reactivation of previous healed tracks, (recurrent drainage 
after complete perianal remission), the need for subsequent 
seton placement performed in EUA, due to new fistulas or 
or the occurrence of perianal abscesses after healing during 
the follow-up period. 
Statistical analysis
Demographic data was described in frequency tables, 
and the occurrence of  perianal complete remission was 
analyzed with Confidence intervals (CI) of 95%. Log-rank 
analysis was performed to check the recurrence rates, as well 
as the Kaplan-Meier method in relation to the timing of its 
occurrence. These analysis were performed with the software 
Statistica package, version 8.0.
Ethical considerations
This study was previously approved by the Ethics Re-
search Committee of  the Catholic University of  Paraná, 
under reference number 11909/2012, via the central website 
from the Brazilian ministry of  health (Plataforma Brasil). 
There was no need for informed consent, as data was retro-
spectively gathered from eletronic charts.
RESULTS
Patients’ characteristics
Initially, 83 consecutive patients with PFCD, in the period 
of the study, were identified after perianal procedures. From 
those, five were excluded from the analysis as they had prima-
ry fistulotomies performed, due to superficial intersphincteric 
fistulas, instead of EUA with seton placement. Overall, the 
study sample was composed of 78 PFCD patients that ful-
filled the inclusion criteria.
The baseline characteristics of  the 78 patients are de-
scribed in Table 1. The population of the study was mostly 
FIGURE 1. Seton placed (red), fixation with overlapping technique with 
simple strings knots (black).
TABLE 1. Baseline characteristics of the 78 patients enrolled in the analysis
Demographics
    Median age at first EUA (years) 33.8 (2-80)
    Male gender (n/%) 34 (44.2%)
    Female gender (n/%) 44 (55.8%)
    CD duration at first EUA (months) 88.9 (0-300)
    Mean Follow-up (months) 48.2 (2-228)
Montreal classification (n/%)
    A1 17 (21.8%)
    A2 39 (50%)
    A3 22 (28.2%)
    L1 11 (14.1%)
    L2 6 (7.7%)
    L3 61 (78.2%)
    L4 0 (0%)
    B1 32 (41%)
    B2 20 (25.7%)
    B3 26 (33.3%)
    Perianal CD 78 (100%)
Smoking and medications (n/%)
    Smoking 8 (10.3%)
    Concomitant azathioprine 60 (76.6%)
    Steroids at first EUA 26 (33.3%)
Type of fistulas (n/%)
    Simple 26 (33.3%)
    Complex 52 (66.7%)
Biological agent used (n/%)
    IFX 49 (62.8%)
    ADA 29 (37.2%)
CD: Crohn’s disease; IFX: Infliximab; ADA: Adalimumab.
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composed by young patients, with primary ileocolic and 
penetrating CD (Montreal classification A2, L3 and B1 were 
the most common characteristics observed). It was also note-
worthy that the vast majority of the patients had complex 
fistulas and were treated with IFX (2/3 of  our sample for 
each variable). The mean follow-up period of the study was 
48.2 months (2-228).
Surgical characteristics
The number of  EUA with seton placements varied from 
1 to 12 (median number 2.7) per patient, with the majority 
of  patients (aproximately 60%) having one or two proce-
dures during follow-up (Table 2). Moreover, the number of 
setons placed per patient varied from one to seven (median 
number two per patient), with the majority of  patients 
(aproximately 77%) having one or two setons placed (Ta-
ble 3). From the 51 patients that have their setons removed, 
the average time for seton withdrawal was 7.3 months (1-36 
months, SD = 6.4). Only 41 of them presented with perianal 
complete remission, and 10 persisted with active discharge 
from the fistulas after seton withdrawal. This means that 
TABLE 2. Number of setons placed per patient, time for seton withdrawal and number of EUA per patient. EUA: examination under anesthesia
Variable n Average Median Minimum Maximum Standard deviation
Number of setons 78 2.0 1.0 1.0 7.0 1.4
Time for seton withdrawal (months) 51 7.3 6.0 1.0 36.0 6.4
Number of EUA per patient 78 2.7 2.0 1.0 12.0 2.3
FIGURE 2. Patient examination after combined therapy, with complete 
perianal remission. Immediate postoperative aspect after last examination 
under anesthesia.
TABLE 3. Number of setons placed per patient, with correspondent 
percentages
Number of setons 
placed per patient Patients (n) Frequency (%)
1 41 52.6
2 19 24.4
3 8 10.3
4 3 3.8
5 5 6.4
6 1 1.3
7 1 1.3
Total 78 100.0
27 patients did not have their setons removed, mainly for 
patient’s option or physicians’ decision (presence of  active 
purulent discharge). Figure 2 demonstrates a patient with 
complete perianal remission.
Primary objective - perianal complete remission
From the 78 patients included, 41 (52.6%) presented 
complete perianal remission (complete healed perineum, 
without active fistulas, drainage or setons). The remaining 
37 patients (47.4%) were considered to have active disease 
(n = 29) or partial response (absence of fistula drainage but 
persistence of the seton as a patient’s option) (n = 8). These 
results are demonstrated in Figure 3.
Recurrence
Recurrence was observed in only four patients of  the 
41 that presented complete perianal remission (9.8% of the 
cases; 95% C.I. 0.7% - 18.8%). The average period for its oc-
currence was 74.8 months. The Kaplan-Meier curve in Figure 
4 demonstrates the cumulative proportion of recurrence. It is 
clear that on the median follow-up of 4 years observed in the 
FIGURE 3. Primary objective of the study. Perianal complete remission 
(defined as absence of drainage and seton withdrawal) was observed in 
52.6% of the patients.
FIGURE 4. Kaplan-Meier curve demonstrating recurrence rates after 
perianal complete remission, observed in 4/41 (9.8%) patients (95% C.I. 
0.7 - 18.8).
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study, approximately 97% of the patients tended to maintain 
perianal complete remission.
DISCUSSION
Perianal fistulas still remain one of the most challenging 
forms of Crohn´s disease, even with the significant advances 
in medical therapy that occurred in the last 15 years. Most 
of the data in the literature are based on non-randomized 
trials, and clinical practice has been driving the management 
of this phenotype of CD more recently(22).
Data regarding direct comparison of different treatment 
strategies in PFCD are limited. Most of  the studies with 
conventional therapy, such as antibiotics and immunomodu-
lators, were based on observational case series, and the few 
randomized trials were performed in small samples, with 
conflicting results(4, 14, 15, 21). However, even with significant 
methodological biases from these previous experiences, there 
is almost a consensus that medical or surgical therapy in iso-
lation present limited results in the management of PFCD. 
The concept of  combined therapy between medications 
and different surgical techniques was developed during the 
last decades, and is the most common strategy performed 
nowadays(22).
The classification of perianal fistulas in CD (in the pre-
sent study, based on the AGA technical note, that divides 
the fistulas in simple or complex) is essential to select the 
patients that would benefit from a combined approach with 
surgery and anti-TNF agents. This classification is widely 
used due to its simplicity and easiness of appliance in daily 
clinical practice(1).
The management of  PFCD with combined therapy 
(anti-TNFs and seton placement) is not needed in every 
patient with perianal fistulas in CD. The European Crohn’s 
and Colitis Organisation (ECCO) guidelines even describe 
anti-TNF agents as a second line medical therapy after 
EUA(22). Patients with superficial intersphincteric fistulas can 
be easily submitted to fistulotomies associated with conven-
tional medical therapy (antibiotics or immunomodulators) 
with favorable results. That was observed in five patients of 
our study’s population, that were excluded from the main 
analysis. These kind of patients do not need to initiate bi-
ological therapy, with the risk of  overtreatment, potential 
adverse events and increased costs.
Therefore, the classification of the type of the fistulas is 
extremely important in order to identify properly the patients 
with complex fistulas, with concomitant proctitis, that will 
have their treatment to be directed towards an anti-TNF 
agent after the surgical procedure. Complementary tests such 
as MRI and endorectal ultrasound, associated with EUA, can 
help to better identify these patients, that are ideal candidates 
for the combined approach.
The treatment target of  PFCD is variable on several 
studies from the literature. In a study to verify the efficacy 
of IFX in the management of complex fistulas, Present et 
al. aimed to check a reduction in 50% of the drainage from 
the fistula tracks(16). In the ACCENT II study, equally per-
formed with IFX, the primary objective was the same(19). 
Other studies aimed to verify a reduction in the number of 
fistulas after therapy. The target of “complete healing” of the 
fistulas is also limited by the fact that even after the absence 
of drainage of the fistulas, MRI can identify the presence of 
active inflammation inside the tracks, which means that even 
with absence of drainage, the fistulas could be not actually 
healed(23).
In this scenario of  heterogeneous objectives with sig-
nificant limitations in the definition of  the proper target, 
the objective of our study was to identify patients without 
active drainage associated with seton withdrawal, and that 
was defined as perianal complete remission. That means 
that patients could even have active disease elsewhere in the 
digestive track, after achievement of complete remission of 
the perianal fistulas. We believe that this could be the best 
outcome to be identified in an observational retrospective 
case series. Talbot et al., classified the results after therapy in 
complete, partial or absent response(20). Hyder et al., aimed 
a reduction in the Perianal Crohn’s disease Activity Index 
(PDAI), a more objective measurement that was not used in 
our study due to its retrospective design(9). Other interesting 
studies had demonstrated that an objective measurement 
of  inflammation in the perianal fistulas with MRI can be 
more precise, and maybe this can be better studied in a pros-
pective future trial(13). No patients from the present study’s 
sample was submitted to MRI after the procedures, to check 
inflammation.
The association of antibiotics with combined therapy is 
another important theme of debate in the management of 
PFCD. Some studies demonstrated the results of case series 
of patients that used antibiotics (ciprofloxacin or metronida-
zole) for 1 or 2 weeks after the first IFX infusion(2, 7, 8). One 
prospective study even demonstrated that the association 
of ciprofloxacin for 12 weeks with ADA had lead to better 
results than monotherapy with ADA in this scenario(6). In 
the present study, we did not look for the use of concomi-
tant antibiotics after surgery in the long term. All patients 
included had used metronidazole or ciprofloxacin for at least 
a short period after the procedures (2 weeks). A future pro-
spective trial would had to include the strategy of combined 
antibiotics with anti-TNFs after the EUA, according to the 
previous experience from the ADAFI study(6).
Complete perianal remission was found in 52.6% of our 
patients. This number is similar to the rates found in the lit-
erature, in retrospective studies. Talbot et al. described 47% 
of complete response to the treatment(20), and Gaertner et 
al., in the subgroup that received IFX after seton placement, 
described aproximately 42% of  complete healing, in 112 
patients(8). On the other hand, Antakia et al. demonstrated a 
29% rate of complete response and 42% of partial remission 
in a sample of 48 patients(2). Hyder et al. described only 18% 
of sustained fistula healing, maybe due to the short follow-up 
period in their study(9). Our favorable results can be really 
considered, as compared to other studies, due to the longer 
follow-up period and also to the individualized strategy 
that was undertaken, regarding the seton withdrawal in an 
Kotze PG, Albuquerque IC, Moreira AL, Tonini WB, Olandoski M, Coy CSR.  
Perianal complete remission with combined therapy (seton placement and anti-TNF agents) in Crohn’s disease: a Brazilian multicenter observational study
288 Arq Gastroenterol v. 51 no. 4 - out./dez. 2014
optimal timing as well as a repetition of the EUA whenever 
needed according to the surgeon’s decision. This tight con-
trol individualized strategy can justify our rates of complete 
peria nal remission, that could be even underestimated, main-
ly due to the fact that patients without active drainage that 
wanted to keep their setons were allowed to do it (incomplete 
remission), what may had lowered the rates of success.
Recurrence occurred in only four of the 41 patients that 
had achieved perianal complete remission (9.8%) during a 
median follow-up of approximately 4 years. Data from pre-
vious studies regarding recurrence are quite heretogeneous, 
and difficult to interpret, mainly because of different study 
designs and different surgical strategies. Antakia et al. de-
scribed 25% of reccurrence after total remission, and 45% 
in partial responders, in a median follow-up of 20 months(2). 
Talbot et al. described no recurrence in the 10 patients with 
total remission, with a similar follow-up period(20). The du-
rable maintenance of complete perianal remission with low 
recurrence rates in our study can be justified by the previous 
imaging tests in all patients, that helped to better identify 
secondary hidden fistula tracks. This strategy probably 
reduced the rates of perianal abscesses after the first EUA, 
that could occur in a significant portion of  patients with 
occult fistula tracks. Moreover, the possibility to repeat the 
EUA when needed and the seton withdrawal being mostly 
performed later on during the follow-up also contributed to 
our low recurrence rates. No patients in our population had 
to undergone to proctectomy during follow-up.
Two previous retrospective studies decided to perform 
seton withdrawal after two IFX infusions(2, 9). That was not 
the strategy in our study, and there is no consensus on the 
proper timing for that therapeutical step. The decision of the 
proper timing of seton withdrawal was based on the surgeons’ 
perception of active drainage and active proctitis, and was 
not standardized. The average period for withdrawal of the 
setons was 7.3 months, varying from 1 to 36 months. Moreo-
ver, the number of sequential EUA performed was equally 
different from other studies. In our observational case series, 
the average number of surgical procedures was 2.7 (varying 
from 1 to 12). We believe that the timing of seton withdrawal 
and the number of procedures during combined therapy are 
other controversial issues that need to be better studied in 
future prospective trials.
Our study had clear limitations, mainly due its retrospec-
tive, observational and multicentric design. Additionally, 
the patients did not have exactly the same treatment during 
follow-up. The variable number of  EUA, and the individ-
ualized decision of the proper timing of seton withdrawal 
could possibly have made this sample heterogeneous in some 
aspects. Moreover, we did not perform MRI tests after the 
procedures, in order to check active inflammation inside 
the fistula tracks before seton withdrawal. Perianal fistulas 
compose a very heterogeneous phenotype of CD. Therefore, 
it is very difficult to standardize the therapy for every patient.
In summary, in this multicenter observational study, peri-
anal complete remission was observed in 52.6% of PFCD 
patients submitted to combined therapy, with EUA and seton 
placement followed by anti-TNF therapy with IFX or ADA, 
and only 9.8% of these patients developed recurrence. The 
findings of  our study, that must be interpreted with cau-
tion, suggest that the combination of seton placement with 
subsequent anti-TNF therapy lead to favorable and durable 
results in a significant proportion of patients. Individualized 
case-to-case based decisions, mainly regarding the optimal 
timing for seton withdrawal, and the possibility to repeat the 
EUA whenever needed, are possible reasons for the promising 
results achieved in this case series, and can be better studied 
in future prospective trials.
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biológicos) na doença de Crohn: um estudo brasileiro observacional e multicêntrico. Arq Gastroenterol. 2014,51(4):283-9.
RESUMO – Contexto - A doença de Crohn perianal fistulizante é uma das formas mais graves das doenças inflamatórias intestinais. A terapia combinada 
com sedenhos e agentes biológicos é a estratégia mais comumente empregada para essa condição. Objetivo - O objetivo deste estudo foi analisar as taxas 
de remissão perianal completa com a terapia combinada na doença de Crohn perianal fistulizante. Métodos - Trata-se de um estudo retrospectivo e 
observacional com portadores de doença de Crohn perianal fistulizante submetidos à terapia combinada provenientes de quatro centros de referência 
do Brasil. Foram analisadas as características de base dos pacientes, classificação de Montreal, medicamentos concomitantes, classificação das fístulas, 
ocorrência de remissão perianal completa e recorrência. Remissão perianal completa foi definida como ausência de drenagem das fístulas associada 
à retirada dos sedenhos. Discussão - Foram incluídos 78 pacientes, 44 (55,8%) mulheres, com média de idade de 33,8 (±15) anos. A maior parte dos 
pacientes foi tratada com Infliximabe, 66,2%, do que com Adalimumabe, 33,8%. Fístulas complexas foram observadas em 52/78 (66,7%) pacientes. 
Após um seguimento médio de 48,2 meses, 41/78 (52,6%) pacientes apresentaram remissão perianal completa (IC 95%: 43,5%–63,6%). Recorrência 
foi observada em quatro (9,8%) pacientes (IC 95%: 0,7%–18,8%) em um período médio de 74,8 meses para sua ocorrência. Conclusão - A terapia 
combinada trouxe resultados favoráveis e duradouros em portadores de doença de Crohn perianal fistulizante.
DESCRITORES – Doença de Crohn. Fator de necrose tumoral alfa. Fístula retal. 
Kotze PG, Albuquerque IC, Moreira AL, Tonini WB, Olandoski M, Coy CSR. 
Perianal complete remission with combined therapy (seton placement and anti-TNF agents) in Crohn’s disease: a Brazilian multicenter observational study
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